



## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/756,551	01/08/2001	Casey D. Morrow	UAI-004CPDV2CN	6750
25225	7590 03/25/2003			
MORRISON & FOERSTER LLP			EXAMINER	
SUITE 500	Y CENTRE DRIVE		WOITACH, JOSEPH T	
SAN DIEGO	, CA 92130-2332		ART UNIT	PAPER NUMBER
			1632	
			DATE MAILED: 03/25/2003	14

Please find below and/or attached an Office communication concerning this application or proceeding.





File

Office Action Summary

Application No. **09/756,551** 

Applicant(s)

Examiner

Art Unit


Joseph Woitach

1632

Morrow et al.

,	
• •	s on the cover sheet with the correspondence address
Period for Reply	T TO EVENE 4
A SHORTENED STATUTORY PERIOD FOR REPLY IS SETHE MAILING DATE OF THIS COMMUNICATION.	I TO EXPIRE MONTH(S) FROM
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a).	In no event, however, may a reply be timely filed after SIX (6) MONTHS from the
mailing date of this communication.  - If the period for reply specified ebove is less than thirty (30) days, a reply within	the statutory minimum of thirty (30) days will be considered timely.
<ul> <li>If NO period for reply is specified above, the maximum statutory period will apply</li> <li>Failure to reply within the set or extended period for reply will, by statute, cause</li> </ul>	· · · · · · · · · · · · · · · · · · ·
<ul> <li>Amy repty received by the Office later than three months after the mailing date of earned patent term adjustment. See 37 CFR 1.704(b).</li> </ul>	f this communication, even if timely filed, may reduce any
Status	
1) X Responsive to communication(s) filed on <u>Jan 7, 2</u>	003
2a) ☐ This action is <b>FINAL</b> . 2b) ☒ This action	ction is non-final.
3) $\square$ Since this application is in condition for allowance closed in accordance with the practice under Ex p	except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposition of Claims	
4) 💢 Claim(s) <u>49-63</u>	is/are pending in the application.
	is/are withdrawn from consideration.
5)  Claim(s)	is/are allowed.
6)  Claim(s)	is/are rejected.
7)	is/are objected to.
8) 💢 Claims <u>49-63</u>	are subject to restriction and/or election requirement.
Application Papers	
9) $\square$ The specification is objected to by the Examiner.	
10) The drawing(s) filed on Jan 8, 2001 is/ar	re a) $ ot\!\! $ accepted or b) $ ot\!\!$ objected to by the Examiner.
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See 37 CFR 1.85(a).
11) The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.
If approved, corrected drawings are required in reply	to this Office action.
12) $\square$ The oath or declaration is objected to by the Example 12.	niner.
Priority under 35 U.S.C. §§ 119 and 120	
13)☐ Acknowledgement is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d) or (f).
a) $\square$ All b) $\square$ Some* c) $\square$ None of:	
<ol> <li>Certified copies of the priority documents have</li> </ol>	eve been received.
2.   Certified copies of the priority documents ha	eve been received in Application No
application from the International Bur	
*See the attached detailed Office action for a list of t	
14) Acknowledgement is made of a claim for domesti	
a) ☐ The translation of the foreign language provisior  15) ☒ Acknowledgement is made of a claim for domesti	
	c priority under 35 0.3.C. 33 120 and/or 121.
Attachment(s)  1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	6)  Other:





Art Unit: 1632

## **DETAILED ACTION**

This application is a continuation of 09/376,184, filed August 17, 1999, now abandoned, which is a continuation of 08/987,867, filed December 9, 1997, now patent number 6,063,384, which is a continuation of 08/389,459, filed February 15, 1995, now patent number 5,817,512, which is a continuation of 08/087,009, filed July 1, 1993, now abandoned.

Applicants amendment filed January 7, 2003, paper number 13, has been received and entered. Claims 35-39 and 45-48 have been canceled. Claims 49-63 are pending and currently under examination. Amendments to the claims in Applicants' amendment filed August 26, 2002, paper number 10, has necessitated a new restriction requirement.

## Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 49, 50, 53, 55-63, drawn to a method for expressing a gene in a cell in culture, classified in class 435, subclass 69.1.
- II. Claims 49-63, drawn to a method for expressing a gene in a cell of a subject by administering to a subject a poliovirus directly or by providing a cell infected with poliovirus, classified in class 514, subclass 44, class 424, subclass 93.1.

Claims 49, 50, 53 and 55-63 are generic to both inventions and will be examined to the extent that they encompass the elected invention.



Page 3



Application/Control Number: 09/756,551

Art Unit: 1632

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the methods are drawn to two different and distinct methods requiring different materials and different method steps to practice.

In addition, if either group is elected, an election of species is required. This application contains claims directed to the following patentably distinct species of the claimed invention: the claims recite and encompass the expression of various encoded sequences. Specifically, Applicants must elect: one protein selected from the group of IL-1, IL-2, IL-6, interferon-7, and a structural gene; or one antisence gene selected from the group of an HIV gene and oncogene; or one ribozyme selected from the group of endonuclease or polymerase.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 49, 50, 53 and 55 are generic to both groups I and II, and claims 51, 52 and 54 are generic to group II.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable





Page 4

Application/Control Number: 09/756,551

Art Unit: 1632

thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above have acquired a separate status in the art as shown by their different classification and divergent subject matter restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).





Page 5

Application/Control Number: 09/756,551

Art Unit: 1632

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (703)305-3732.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at (703)305-4051.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (703) 308-2141.

Papers related to this application may be submitted by facsimile transmission. Papers should be faxed via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center numbers are (703)308-4242 and (703)305-3014.

Joseph T. Woitach

Joe Wortall